Dynamic Technology Lab Private Ltd Sells 721 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Dynamic Technology Lab Private Ltd lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,226 shares of the specialty pharmaceutical company’s stock after selling 721 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Collegium Pharmaceutical were worth $241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Penserra Capital Management LLC bought a new stake in Collegium Pharmaceutical in the 3rd quarter valued at $757,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 4.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock worth $14,741,000 after purchasing an additional 16,655 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Collegium Pharmaceutical by 17.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after buying an additional 116,327 shares in the last quarter. Foundry Partners LLC boosted its stake in Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after buying an additional 509 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Collegium Pharmaceutical during the 3rd quarter valued at approximately $374,000.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $30.50 on Monday. The firm has a market capitalization of $983.63 million, a PE ratio of 13.15 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 12-month low of $25.21 and a 12-month high of $42.29. The firm has a 50-day moving average price of $34.94 and a 200-day moving average price of $34.62. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on COLL shares. HC Wainwright increased their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 13.81 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.